GBIM लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (15 Mar 2024 @ 00:13):

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform...

Stats
आज की मात्रा	756.00
औसत मात्रा	0.00
बाजार मूल्य	10 065.00
EPS	$-0.150 ( 2016-05-12 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2016-03-16	Mitchell Daniel J	Sell	8 862	Common Stock
2016-03-17	Mitchell Daniel J	Sell	12 468	Common Stock
2016-03-16	Mitchell Daniel J	Sell	112	Common Stock
2016-03-17	Mitchell Daniel J	Sell	158	Common Stock
2016-03-11	Mitchell Daniel J	Sell	76 662	Common Stock

INSIDER POWER
0.00
Last 99 transactions
Buy: 1 518 952 \| Sell: 29 605 418

मात्रा सहसंबंध

लंबा: -0.32 (neutral)

छोटा: 0.21 (neutral)

Signal:(24.043) Neutral

GlobeImmune, Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

GlobeImmune, Inc. सहसंबंध - मुद्रा/वस्त्र

0.00
( neutral )

GlobeImmune, Inc. वित्तीय

Annual	2022
राजस्व:	$0
सकल लाभ:	$0 (0.00 %)
EPS:	$0

FY	2022
राजस्व:	$0
सकल लाभ:	$0 (0.00 %)
EPS:	$0

FY	2015
राजस्व:	$6.46M
सकल लाभ:	$6.46M (100.00 %)
EPS:	$-0.480

FY	2014
राजस्व:	$5.97M
सकल लाभ:	$5.97M (100.00 %)
EPS:	$-5.58

Financial Reports:

No articles found.

GlobeImmune, Inc.

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.